A South African clinical trial was significantly altered when it found that survival rates are better among HIV-positive children who begin treatment immediately, as opposed to delaying based on CD4 cell counts. Researchers shut down the deferred treatment arm of the study after just eight months to get all in need kids on meds; it’s not yet clear how the findings will affect HIV pediatric care in the United States.